CANASA Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Canasa, and when can generic versions of Canasa launch?

Canasa is a drug marketed by Abbvie and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has thirteen patent family members in twelve countries.

The generic ingredient in CANASA is mesalamine. There are twenty-eight drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the mesalamine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Canasa

A generic version of CANASA was approved as mesalamine by PADAGIS ISRAEL on September 17^th, 2004.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for CANASA?
What are the global sales for CANASA?
What is Average Wholesale Price for CANASA?

Summary for CANASA

International Patents:	13
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	181
Clinical Trials:	2
Drug Prices:	Drug price information for CANASA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CANASA
What excipients (inactive ingredients) are in CANASA?	CANASA excipients list
DailyMed Link:	CANASA at DailyMed

Drug patent expirations by year for CANASA

Recent Clinical Trials for CANASA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sandoz	Phase 3
Axcan Pharma	Phase 3
Forest Laboratories	Phase 3

See all CANASA clinical trials

Pharmacology for CANASA

Drug Class	Aminosalicylate

Paragraph IV (Patent) Challenges for CANASA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CANASA	Suppository	mesalamine	1000 mg	021252	1	2013-05-24

US Patents and Regulatory Information for CANASA

CANASA is protected by two US patents.

Patents protecting CANASA

Mesalamine suppository
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	CANASA	mesalamine	SUPPOSITORY;RECTAL	021252-002	Nov 5, 2004	AB	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Abbvie	CANASA	mesalamine	SUPPOSITORY;RECTAL	021252-002	Nov 5, 2004	AB	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Abbvie	CANASA	mesalamine	SUPPOSITORY;RECTAL	021252-001	Jan 5, 2001		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for CANASA

See the table below for patents covering CANASA around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Russian Federation	2012125186	МЕСАЛАМИНОВЫЙ СУППОЗИТОРИЙ	⤷ Sign Up
South Africa	201204422	MESALAMINE SUPPOSITORY	⤷ Sign Up
Japan	2013514979		⤷ Sign Up
Canada	2784772	SUPPOSITOIRE DE MESALAMINE (MESALAMINE SUPPOSITORY)	⤷ Sign Up
Australia	2010339837	Mesalamine suppository	⤷ Sign Up
Japan	2013514979		⤷ Sign Up
Australia	2010339837	Mesalamine suppository	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration